Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Combination ranolazine and dronedarone to suppress atrial fibrillation.

Lepor NE.

Rev Cardiovasc Med. 2011;12(2):e118-20. No abstract available.

PMID:
21796082
2.

Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.

Dale KM, White CM.

Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. Review.

PMID:
17389667
3.

Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.

Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH; ATHENA Investigators.

Circulation. 2009 Sep 29;120(13):1174-80. doi: 10.1161/CIRCULATIONAHA.109.875252. Epub 2009 Sep 14.

4.

Dronedarone: drondarone, SR 33589, SR 33589B.

[No authors listed]

Drugs R D. 2007;8(3):171-5. Review.

PMID:
17472412
5.

A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.

Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD.

J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):24S-30S. doi: 10.1177/1074248410368276. Review.

PMID:
21098416
6.

Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.

Kumar K, Nearing BD, Carvas M, Nascimento BC, Acar M, Belardinelli L, Verrier RL.

J Cardiovasc Electrophysiol. 2009 Jul;20(7):796-802. doi: 10.1111/j.1540-8167.2009.01437.x. Epub 2009 Feb 27.

PMID:
19298570
7.

Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation.

Duray GZ, Ehrlich JR, Hohnloser SH.

Curr Opin Cardiol. 2010 Jan;25(1):53-8. doi: 10.1097/HCO.0b013e32833354e4. Review.

PMID:
19881340
8.

Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.

Duray GZ, Schmitt J, Hohnloser SH.

J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):19S-23S. doi: 10.1177/1074248410368530. Epub 2010 May 14.

PMID:
20472812
9.

Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.

Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, Van Kempen L; ERATO Study Investigators.

Am Heart J. 2008 Sep;156(3):527.e1-9. doi: 10.1016/j.ahj.2008.06.010.

PMID:
18760136
10.

Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart.

Carvas M, Nascimento BC, Acar M, Nearing BD, Belardinelli L, Verrier RL.

J Cardiovasc Pharmacol. 2010 Mar;55(3):286-91. doi: 10.1097/FJC.0b013e3181d26416.

PMID:
20075744
11.

Perspective: does ranolazine have potential for the treatment of atrial fibrillation?

Hancox JC, Doggrell SA.

Expert Opin Investig Drugs. 2010 Dec;19(12):1465-74. doi: 10.1517/13543784.2010.535517. Review.

PMID:
21105855
12.

Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?

Singh D, Cingolani E, Diamond GA, Kaul S.

J Am Coll Cardiol. 2010 Apr 13;55(15):1569-76. doi: 10.1016/j.jacc.2009.10.071. Review.

13.

Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).

Page RL, Connolly SJ, Crijns HJ, van Eickels M, Gaudin C, Torp-Pedersen C, Hohnloser SH; ATHENA Investigators.

Am J Cardiol. 2011 Apr 1;107(7):1019-22. doi: 10.1016/j.amjcard.2010.11.028. Epub 2011 Feb 4.

PMID:
21296333
14.

Dronedarone: an emerging agent with rhythm- and rate-controlling effects.

Wegener FT, Ehrlich JR, Hohnloser SH.

J Cardiovasc Electrophysiol. 2006 Sep;17 Suppl 2:S17-20. Review.

PMID:
16939434
15.

Dronedarone.

Patel C, Yan GX, Kowey PR.

Circulation. 2009 Aug 18;120(7):636-44. doi: 10.1161/CIRCULATIONAHA.109.858027. Review.

16.

Dronedarone for the management of atrial fibrillation.

Brenner R, Delacrétaz E.

Swiss Med Wkly. 2011 Mar 2;141:w13158. doi: 10.4414/smw.2011.13158. Review.

17.

Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?

Ehrlich JR, Nattel S.

Curr Opin Cardiol. 2009 Jan;24(1):50-5. doi: 10.1097/HCO.0b013e32831bc336. Review.

PMID:
19077816
18.

Dronedarone: an alternative to amiodarone?

Hughes PJ, Freeman MK, Cohenour FV, Price EM.

Consult Pharm. 2010 Sep;25(9):555-69. doi: 10.4140/TCP.n.2010.555. Review.

PMID:
20876046
19.

Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.

Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH; EURIDIS and ADONIS Investigators.

N Engl J Med. 2007 Sep 6;357(10):987-99.

20.

The novel antiarrhythmic drug dronedarone: comparison with amiodarone.

Kathofer S, Thomas D, Karle CA.

Cardiovasc Drug Rev. 2005 Fall;23(3):217-30. Review.

PMID:
16252015

Supplemental Content

Support Center